ArticleMolecular pharmaceutics2013
RNA replicon delivery via lipid-complexed PRINT protein particles.
Article in Molecular pharmaceutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- mRNA Vaccines in Cancer Immunotherapy: Recent Advances, Clinical Translation, and Future Perspectives.Current medical science · 2025Review
- mRNA vaccine in cancer therapy: Current advance and future outlook.Clinical and translational medicine · 2023Review
- Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action.Current topics in microbiology and immunology · 2022Article
- A Review of Nanotechnology for Treating Dysfunctional Placenta.Frontiers in bioengineering and biotechnology · 2022Review
- Molecular Perspective of Nanoparticle Mediated Therapeutic Targeting in Breast Cancer: An Odyssey of Endoplasmic Reticulum Unfolded Protein Response (UPRBiomedicines · 2021Review
- Recent advances in nanotheranostics for triple negative breast cancer treatment.Journal of experimental & clinical cancer research : CR · 2019Review
- Polymeric Nanoparticles in Gene Therapy: New Avenues of Design and Optimization for Delivery Applications.Polymers · 2019Review
- Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Review
- Anisotropic biodegradable lipid coated particles for spatially dynamic protein presentation.Acta biomaterialia · 2018Article
- Cancer nanomedicine: a review of recent success in drug delivery.Clinical and translational medicine · 2017Review
- The notorious R.N.A. in the spotlight - drug or target for the treatment of disease.RNA biology · 2017Review
- Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Control of polymeric nanoparticle size to improve therapeutic delivery.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- Biomimetic particles as therapeutics.Trends in biotechnology · 2015Review
- An automated multidimensional thin film stretching device for the generation of anisotropic polymeric micro- and nanoparticles.Journal of biomedical materials research. Part A · 2015Article
- Contemporary approaches for nonviral gene therapy.Discovery medicine · 2015Review
- Biodistribution and Toxicity Studies of PRINT Hydrogel Nanoparticles in Mosquito Larvae and Cells.PLoS neglected tropical diseases · 2015Article
- Self-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic Nanoparticles.Vaccines · 2014Review
- Engineered PRINT(®) nanoparticles for controlled delivery of antigens and immunostimulants.Human vaccines & immunotherapeutics · 2014Article
- Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles.International journal of nanomedicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Herein we report the development of a nonviral lipid-complexed PRINT (particle replication in nonwetting templates) protein particle system (LPP particle) for RNA replicon delivery with a view toward RNA replicon-based vaccination. Cylindrical bovine serum albumin (BSA) particles (diameter (d) 1 μm, height (h) 1 μm) loaded with RNA replicon and stabilized with a fully reversible disulfide cross-linker were fabricated using PRINT technology. Highly efficient delivery of the particles to Vero cells was achieved by complexing particles with a mixture of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) lipids. Our data suggest that (1) this lipid-complexed protein particle is a promising system for delivery of RNA replicon-based vaccines and (2) it is necessary to use a degradable cross-linker for successful delivery of RNA replicon via protein-based particles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.